DXCM DEADLINE: DexCom, Inc. Investors with Losses are Notified to Contact BFA Law before December 26 Securities Class Action Deadline

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud due to significant stock drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [4]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and posing health risks to customers [5]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to revelations about product quality issues, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [6]. - After the FDA published details of unauthorized modifications on March 25, 2025, the stock fell another $3.19 per share (over 4%) [7]. - A report by Hunterbrook on September 18 revealed severe issues, leading to a nearly 12% drop of $8.99 per share over two trading days [8].